We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Developed Immunoassay Predicts Benefits of Anti-PD-1 Therapy in NSCLC

By LabMedica International staff writers
Posted on 12 May 2021
Print article
Image: The HISCL-5000 is a fully automated immunoassay system designed for fast, highly sensitive and reliable immunoassay testing (Photo courtesy of Sysmex)
Image: The HISCL-5000 is a fully automated immunoassay system designed for fast, highly sensitive and reliable immunoassay testing (Photo courtesy of Sysmex)
Lung cancer is the most common cause of cancer-related deaths worldwide. However, current targeted therapies and immunotherapies have gradually improved patient survival. Anti-programmed cell death-1 (PD-1) antibodies (Abs) are key drugs in non-small-cell lung cancer treatment; however, clinical benefits with anti-PD-1 monotherapy are limited.

Notably, anti-programmed cell death-1 (PD-1) and anti-PD-ligand1 (PD-L1) antibodies (Abs) as immune-checkpoint inhibitors prolong overall survival in non-small-cell lung cancer (NSCLC), which accounts for approximately 80% of lung cancer. However, clinical benefits with anti-PD-1/PD-L1 monotherapy are limited with only 20%–30% overall response rate.

Oncologists at the Kawasaki Medical School, Okayama, Japan and their colleagues obtained sera from advanced NSCLC patients, who received anti-PD-1 monotherapy as standard therapy in a first-line or later setting. Sera were collected within two months before anti-PD-1 monotherapy and were serially done after anti-PD-1 therapy, then frozen and stored at −80 °C until use. ESO-1 and XAGE1 antigen in tumor tissues were immunohistochemically stained in a previous study.

The team developed a fully automated detection system for NY-ESO-1/XAGE1 Abs using an HISCL series (Sysmex, Kobe, Japan), which performs a chemiluminescent sandwich immunoassay. Sera were diluted 400 times with appropriate solution and reacted with magnetic beads coated with recombinant NY-ESO-1 protein or synthetic XAGE1 peptide (GL Biochemistry, Shanghai, China). The investigators also determined serum Abs stability, performed analysis of interfering substances and antigen absorption tests.

The scientists reported that the HISCL system detected specific serum NY-ESO-1/XAGE1 Abs, where levels in ELISA and HISCL were highly correlated. The Ab levels in HISCL were stable at four temperatures, five freeze/thaw cycles, and long-term storage; the levels were not interfered by common blood components. The Abs levels in 15 NSCLC responders to anti-PD-1 monotherapy were significantly higher than those in non-responders and healthy donors. The AUROC was the highest (0.91) in combinatory prediction with NY-ESO-1/XAGE1 Abs.

The authors concluded that they had developed a fully automated immunoassay system, HISCL, measuring serum NY-ESO-1/XAGE1 Abs that can predict clinical benefits with anti-PD-1 monotherapy in NSCLC. Their serum biomarkers measured using HISCL are clinically meaningful, as the serum Abs obtained noninvasively were relatively stable at various conditions and could be measured easily and rapidly. The study was published on April, 15, 2021 in the journal Clinica Chimica Acta.

Related Links:
Kawasaki Medical School
Sysmex
GL Biochemistry


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.